Delving into the Latest Updates on Technetium(99mTc) Tetrofosmin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms

99mTc-tetrofosmin, TECHNETIUM TC-99M TETROFOSMIN KIT, Tc-99m tetrofosmin

+ [9]

Target-

Mechanism

SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

NeoplasmsCardiovascular DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Breast CancerCoronary Artery DiseasePerioperative ischaemia+ [2]

Inactive Indication

Myocardial Infarction

Originator Organization

GE Healthcare Ltd. (United Kingdom)

Active Organization

G&E Healthcare Co., Ltd.GE Healthcare Ltd. (United Kingdom)Medi-Physics, Inc.

+ [2]

Inactive Organization

GE Healthcare ASGE Healthcare (Shanghai) Co. Ltd.

Drug Highest PhaseApproved

First Approval Date

JP (02 Oct 1996),

Diagnostic agents

Regulation-

Login to view timeline

Structure

Molecular FormulaC36H80O10P4Tc

InChIKeyYULJAJIAWLAAKV-INZTZQCYSA-N

CAS Registry127455-27-0

The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).

Start Date01 Jun 2011

Sponsor / Collaborator

Lantheus Medical Imaging, Inc.

NL-OMON37178 / CompletedNot Applicable

Evaluating Myocardial Ischemia and Sympathetic Innervation in Patients with Chronic Kidney Disease before and during Renal Replacement Therapy using 99mTc-tetrofosmin and 123I-MIBG imaging - Myocardial Ischemia Innervation imaging

Start Date10 May 2010

Sponsor / Collaborator

Universitair Medisch Centrum Groningen

100 Clinical Results associated with Technetium(99mTc) Tetrofosmin

Login to view more data

100 Translational Medicine associated with Technetium(99mTc) Tetrofosmin

Login to view more data

100 Patents (Medical) associated with Technetium(99mTc) Tetrofosmin

Login to view more data

807

Literatures (Medical) associated with Technetium(99mTc) Tetrofosmin

22 Sep 2024·BJU international

The use of ^99mTc-tetrofosmin in the characterisation of indeterminate renal masses: a pilot study.

Article

Author: Allaf, Mohamad E ; Sheikhbahaei, Sara ; Solnes, Lilja B ; Jones, Krystyna M ; Gorin, Michael A ; Javadi, Mehrbod S ; Pavlovich, Christian P ; Singla, Nirmish ; Spiro, Ergi ; Rowe, Steven P ; Amindarolzarbi, Alireza ; Murtazaliev, Salikh ; Kaufmann, Basil

This study was approved by the Johns Hopkins Institutional Review Board and all patients signed written, informed consent. Enrolled patients were categorised into two cohorts, comprising a total of 11 subjects.Cohort A consisted of four patients with previously biopsied renal masses demonstrating ′oncocytic neoplasm′. Cohort B consisted of seven patients with cT1 renal masses scheduled to undergo resection.The exclusion criteria prohibited pregnant patients, those with a history of other malignancy with concern for renal metastasis, or those with any known allergy to technetium or tetrofosmin.Patients were asked to be nil per os for approx. 6 h prior to radiotracer injection.Patients were placed supine on the scanner table, 75 min after the i.v. injection of 925 37 MBq (25 1 mCi) of 99mTc-tetrofosmin.A Symbia 16-slice or Intevo 16-slice single-photon emission CT (SPECT)/CT gamma camera (Siemens Healthineers, Erlangen, Germany) were used for all imaging procedures.SPECT imaging was acquired in step and shoot mode, with 25 s per image, utilizing 3 degrees per step over 120 steps and a detector range of 180 degrees per detector.CT images were acquired at 110 kV and 200 mAs with dose care modulation enabled. Images were reconstructed using a 128 9 128-pixel matrix, and the imaging field was focused on the abdomen between the diaphragm and the tops of the iliac crests; 3-mm axial images were reconstructed for both SPECT and CT imaging.

01 Mar 2024·Canadian Journal of Cardiology

Accumulation of Technetium-99m Tetrofosmin on Myocardial Perfusion Scintigraphy in a Patient With Immunoglobulin G4-Related Coronary Periarteritis

Article

Author: Kudo, Kohsuke ; Nagai, Toshiyuki ; Watanabe, Shiro ; Watanabe, Masaya ; Suno, Kenichiro ; Hirata, Kenji ; Fujieda, Yuichiro ; Tsuneta, Satonori

20 Jan 2024·Cureus

Anaphylactic Shock Due to Technetium (99mTc)-Tetrofosmin During Myocardial Perfusion Scintigraphy: A Case Report

Author: Hashimoto, Sho ; Shimoda, Yoshiaki ; Kondo, Morihiko ; Tanaka, Tetsuya ; Tanaka, Mariko

Myocardial perfusion scintigraphy is a popular minimally invasive method for evaluating chronic coronary disease (CCD). We performed myocardial scintigraphy to assess CCD in a 74-year-old man with a history of allergy to contrast media. The patient developed anaphylactic shock immediately after the administration of the technetium (^99mTc)-tetrofosmin preparation. This is the first report of anaphylactic shock due to ^99mTc-tetrofosmin administration during myocardial perfusion scintigraphy.

100 Deals associated with Technetium(99mTc) Tetrofosmin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB09160

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	FI	GE Healthcare Ltd. (United Kingdom)	13 May 2016
Coronary Artery Disease	US	Medi-Physics, Inc.	23 Nov 2001
Perioperative ischaemia	AU	G&E Healthcare Co., Ltd.	26 Aug 1997
Diagnostic agents	JP	Nihon Medi-Physics Co., Ltd.	02 Oct 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myocardial Infarction	Phase 2	CN	GE Healthcare AS	13 Aug 2019
Myocardial Infarction	Phase 2	CN	GE Healthcare (Shanghai) Co. Ltd.	13 Aug 2019
Glioma	Phase 2	-	Pro-Actina SA	-
Brain Cancer	Preclinical	DE	GE Healthcare Ltd. (United Kingdom)	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2019	Not Applicable	Parathyroid Adenoma	-	99mTc-Tetrofosmin	flcpeilyqi(yjkvmlnevl) = ynzfaenjim gmvlmdhsvj (fxiwmuedhi )	-	21 May 2019
SNMMI2014	Not Applicable	-	-	Tc-99m Tetrofosmin	hsisdjlxjk(rsjkwxxqjc) = bytpktayef jzdpsthilv (jxdjzffpmi )	-	05 Nov 2014
AACR2012	Not Applicable	Neoplasms	-	99mTc-tetrofosmin (HPLC method)	onnmxslfhr(maaeigwqob) = vwxiorvpbd uzatodpuku (bfgapdzkog, 2.178% [91.6% - 99.63%])	-	15 Apr 2012
AACR2012	Not Applicable	Neoplasms	-	99mTc-tetrofosmin (TLC SA method)	onnmxslfhr(maaeigwqob) = jeaxdjzefg uzatodpuku (bfgapdzkog, 1.135% [94.31% - 99.86%])	-	15 Apr 2012